Product Details
Mazdutide
Basic Info.
Mazdutide is a dual agonist of the GLP-1receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).
The drug is developed by Eli Lilly and is currently in multiple Phase III studies.
In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.
Areas of Expertise
-
Leading-Edge Manufacturing Capabilityg
-
Advanced R&D and State-of-the-Art Facilities
-
Versatile and Scalable Packaging Solutions
-
Certified Quality & International Compliance
English